The metabolic fuel of paroxysmal nocturnal haemoglobinuria.
glycolysis
metabolic changes
paroxysmal nocturnal haemoglobinuria
urea cycle
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
received:
21
04
2024
accepted:
24
04
2024
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
8
5
2024
Statut:
aheadofprint
Résumé
Metabolic reprogramming has been investigated in haematological malignancies. To date, a few studies have analysed the metabolic profile of paroxysmal nocturnal haemoglobinuria (PNH). The study by Chen and colleagues sheds light on the involvement of metabolic changes in the proliferation of PNH clones. Commentary on: Chen et al. The histone demethylase JMJD1C regulates CPS1 expression and promotes the proliferation of PNH clones through cell metabolic reprogramming. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19477.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Navarro C, Ortega Á, Santeliz R, Garrido B, Chacín M, Galban N, et al. Metabolic reprogramming in cancer cells: emerging molecular mechanisms and novel therapeutic approaches. Pharmaceutics. 2022;14(6):1303.
Tabe Y, Lorenzi PL, Konopleva M. Amino acid metabolism in hematologic malignancies and the era of targeted therapy. Blood. 2019;134(13):1014–1023.
Boët E, Sarry J‐E. Targeting metabolic dependencies fueling the TCA cycle to circumvent therapy resistance in acute myeloid leukemia. Cancer Res. 2024;84(7):950–952.
Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859–1866.
Guarnera L, Jha BK. TET2 mutation as prototypic clonal hematopoiesis lesion. Semin Hematol. 2024;61(1):51–60.
Mishra SK, Millman SE, Zhang L. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets. Blood. 2023;141(10):1119–1135.
He J, Lin M, Zhang X, Zhang R, Tian T, Zhou Y, et al. TET2 is required to suppress mTORC1 signaling through urea cycle with therapeutic potential. Cell Discov. 2023;9(1):84.
Laukka T, Mariani CJ, Ihantola T, Cao JZ, Hokkanen J, Kaelin WG Jr, et al. Fumarate and succinate regulate expression of hypoxia‐inducible genes via TET enzymes. J Biol Chem. 2016;291(8):4256–4265.
Kaplánek R, Kejík Z, Hajduch J, Veselá K, Kučnirová K, Skaličková M, et al. TET protein inhibitors: potential and limitations. Biomed Pharmacother. 2023;166:115324.
Guan Y, Tiwari AD, Phillips JG, Hasipek M, Grabowski DR, Pagliuca S, et al. A therapeutic strategy for preferential targeting of TET2 mutant and TET‐dioxygenase deficient cells in myeloid neoplasms. Blood Cancer Discov. 2021;2(2):146–161.
Caldwell RW, Rodriguez PC, Toque HA, Narayanan SP, Caldwell RB. Arginase: a multifaceted enzyme important in health and disease. Physiol Rev. 2018;98(2):641–665.
Ju H‐Q, Zhan G, Huang A, Sun Y, Wen S, Yang J, et al. ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition. Leukemia. 2017;31(10):2143–2150.
Guarnera L, Santinelli E, Galossi E, Cristiano A, Fabiani E, Falconi G, et al. Microenvironment in acute myeloid leukemia: focus on senescence mechanisms, therapeutic interactions, and future directions. Exp Hematol. 2024;129:104118.
Tabe Y, Konopleva M. Resistance to energy metabolism—targeted therapy of AML cells residual in the bone marrow microenvironment. Cancer Drug Resist. 2023;6(1):138–150.
Bruno S, Mancini M, De Santis S, Monaldi C, Cavo M, Soverini S. The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities. Int J Mol Sci. 2021;22(13):6857.
Tabe Y, Konopleva M, Andreeff M. Fatty acid metabolism, bone marrow adipocytes, and AML. Front Oncol. 2020;10:155.
Chen Y, Liu H, Wang C, Chen W, Li L, Wu J, et al. The histone demethylase JMJD1C regulates CPS1 expression and promotes the proliferation of PNH clones through cell metabolic reprogramming. Br J Haematol. 2024. https://doi.org/10.1111/bjh.19477
Chen M, Zhu N, Liu X, Laurent B, Tang Z, Eng R, et al. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes Dev. 2015;29(20):2123–2139.
Çeliktas M, Tanaka I, Tripathi SC, Fahrmann JF, Aguilar‐Bonavides C, Villalobos P, et al. Role of CPS1 in cell growth, metabolism and prognosis in LKB1‐inactivated lung adenocarcinoma. J Natl Cancer Inst. 2017;109(3):1–9.
Yao S, Nguyen T‐V, Rolfe A, Agrawal AA, Ke J, Peng S, et al. Small molecule inhibition of CPS1 activity through an allosteric pocket. Cell Chem Biol. 2020;27(3):259–268.e5.
Vallejo F, Yuste JE, Teruel‐Montoya R, Luengo‐Gil G, Bohdan N, Espín S, et al. First exploratory study on the metabolome from plasma exosomes in patients with paroxysmal nocturnal hemoglobinuria. Thromb Res. 2019;183:80–85.
Yamakawa PE, Fonseca AR, Guerreiro da Silva IDC, Gonçalves MV, Marchioni DM, Carioca AAF, et al. Biochemical phenotyping of paroxysmal nocturnal hemoglobinuria reveals solute carriers and β‐oxidation deficiencies. PLoS One. 2023;18(8):e0289285.